Longevity Scientist: Aging Is A Disease. We Just Don’t Know How to Treat (yet)
The Beyond Tomorrow Podcast with Julian IssaShow Notes
Joe Betts-LaCroix and Retro Biosciences recently raised funding at a $1.8 billion valuation. In his first podcast appearance since the announcement, Joe shares his vision for extending healthy human lifespan and the breakthroughs driving the longevity industry forward.
Joe Betts-LaCroix explains why aging is becoming a legitimate scientific target. He shares how new discoveries are turning longevity from speculation into measurable biology.
The conversation explores how AI is accelerating research, while highlighting why biology remains one of the hardest problems to solve. Even with smarter models, real-world testing and clinical trials still take time.
Joe also discusses Alzheimer's, partial cellular reprogramming, and the future of longevity medicine. He shares why exercise remains the best longevity tool available today and what the next decade could look like for human health.
Joe is the CEO of Retro Biosciences and a longtime entrepreneur focused on science and technology. His mission is to extend healthy human lifespan and accelerate breakthroughs in aging research.
This episode is brought to you by NADclinic, the go-to destination for longevity and human performance. Check them out at https://nadclinic.com.
What You’ll Learn Why Sam Altman backed Retro Biosciences
The discovery that changed aging research forever
How AI is transforming biotech and longevity
Why curing all diseases in 10 years is unlikely
What Retro's Alzheimer's programs are targeting
Why biology is harder than most people realize
The longevity intervention Joe recommends today
How aging may become a treatable condition
What the longevity industry could look like by 2030
Joe's vision for the future of human health and AI
⏱ Timestamps 00:00 Intro 00:16 AI's Role in Longevity 03:26 Will AI Cure All Diseases? 09:41 Why Biology Is So Hard to Solve 13:17 Building Technology That Matters 15:06 Adding 10 Healthy Years to Life 18:08 Inside Retro's Clinical Trial 19:31 The Different Types of Longevity Companies 22:10 Are We Already in the Singularity? 24:46 Why Investors Are Betting on AI Biotech 26:15 AI as the New Electricity 27:01 The Biggest Risks Facing Longevity 30:54 Why More Competition Is Good 32:44 Solving Alzheimer's Disease 34:26 Aging Biology and Future Therapeutics 38:25 The Biggest Aging Myth 39:41 The Most Underrated Voices in Longevity 40:25 The Best Longevity "Hack" 46:13 The Future of Longevity by 2030 50:49 If Tomorrow Was Your Last Day...
Follow Joe: Website: https://www.retro.bio/ LinkedIn: https://www.linkedin.com/in/bettslacroix X: https://x.com/bettslacroix
Connect with Julian Instagram: https://www.instagram.com/thebeyondtomorrowpodcast/ Instagram: https://www.instagram.com/juliankissa/ LinkedIn: https://uk.linkedin.com/in/julian-issa Website: www.beyondtomorrowpodcast.com Email: [email protected]
Subscribe on Spotify, Apple, and YouTube for more stories from the edge of what is possible.
More from The Beyond Tomorrow Podcast with Julian Issa
Is “AI will destroy humanity” a real risk, or a story we tell ourselves because we haven’t done the hard engineering?
Do we really know enough about GLP-1 drugs? Mike Israetel breaks down the risks and trade-offs, from anhedonia and calorie-deprived diets to cognitive distortion and the myth of a “zero-harm” default.
What if the fastest way to a longer life isn't a miracle drug, but a wartime mentality against aging?
Are we living in a simulation?
What happens when millions of people hand their lives to AI agents, and nobody has built the rules of the road?